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A B S T R A C T
Background: Non-albicans Candida (NAC) spp. in immunocompromised patients are linked to invasive
infections with narrow treatment choice. This study aimed at comparing the oral colonization of NAC
spp. between HIV and non-HIV infected individuals in Mwanza, Tanzania.
Method: Oral rinse of 351 HIV-infected and 639 non-HIV infected individuals were collected between
March and July 2015. Phenotypic identiﬁcations of Candida spp. was done using Candida Chromogenic
agar and conﬁrmed by MALDI-TOF MS.
Results: NAC spp. were detected in 36/351 (10.3%) HIV-infected individuals compared to 28/639 (4.4%)
of non-HIV infected individuals; P=0.0003. In HIV infected individuals, commonly isolated NAC spp. were
Candida tropicalis, 10(2.8%), C. krusei (Issatschenki orientalis) 9(2.6%) and C. glabrata 8(2.3%). While for
non-HIV infected individuals C. dubliniensis 8(1.3%) and C. tropicalis 5(0.9%) were commonly detected. As
CD4 count/ml decreases by one unit the risk of being colonized by NAC spp. among HIV infected
individuals increases by 1% (OR 1.01, 95% CI; 1.001-1.004, P=0.001).
Conclusion: The prevalence of NAC spp. is high among HIV-infected individuals with low CD4 count
placing them at higher risk of invasive infections. Further studies to investigate the role of NAC spp. in
causing invasive infections among immunocompromised patients are recommended.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Background
Oral candidiasis (OC) is one of the major opportunistic fungal
infections that occur in over 90% of the HIV-infected individuals
during the cause of their illness.1 It is one of the Acquired Immune
Deﬁciency Syndromes (AIDS) prognostic indicators and a major
predisposing factor to invasive fungal diseases like blood-stream
Candida infections.2,3 Oral cavity colonization by Candida spp. in
the healthy population ranges from 17%-75% worldwide.4 For
decades, Candida albicans has been the major Candida spp. isolated* Corresponding author. Department of Microbiology and Immunology, Catholic
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petent individuals, accounting for 60%-80% of cases.5,6 The
emergence of non-albicans Candida (NAC) spp. which are more
resistant to azoles causing oral candidiasis is of public health
concern especially in resource constrained settings.2,3 The
common NAC spp. associated with oral candidiasis includes C.
glabrata, C. tropicalis, C. parapsilosis and C. krusei (Issatchenkia
orientalis).7–9
Oral candidiasis is among the indirect indicators for cell-
mediated immunodeﬁciency and estimated to have >90% positive
predictive value for invasive (e.g. blood stream) candidiasis.4,10,11
Blood-stream Candida infections are the fourth-ranking hospital-
related infection with mortality rates higher than bacterial blood-
stream infections in USA.5,12,13 With increased prevalence of
immunocompromised patients in sub-Saharan Africa, there is
widespread use of antifungal agents both for prophylaxis and
treatment purposes.9 This increased use has been associated withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 2
Distributions of Candida spp. among HIV and non HIV infected populations
Candida spp. HIV positive
N = 351, (n/N)%
Health control
N = 639, (n/N)%
P value
C. albicans (265) 119(33.9) 146(22.9) 0.023
C. tropicalis (15) 10(2.8) 5 (0.9) 0.006
I. orientalis (12) 9 (2.6) 3 (0.5) 0.002
C. glabrata (12) 8 (2.3) 4 (0.6) 0.012
C. parapsilosis (11) 7 (1) 4 (0.6) 0.242
C. dubliniesis (11) 3 (0.8) 8 (1.3) 0.763
C. norvegensis (2) 0 2 (0.3) NA
C. lusitaniae (2) 0 2 (0.3) NA
Table 1
Social demographic data of the study population
Variable HIV positive (n = 351) Control (n = 639) P-value
Age (years)
Median (IQR) 38(31-46) 30(26-36) <0.001
Sex
Female 262 462
Male 89 177 0.426
Antibiotic use
Yes 160(45.6%) 33(5.2%)
No 191(54.4%) 606(94.8%) <0.001
CD4
Median(IQR) 372.5(195.5-559.5) NA NA
HAART
Yes 343(97.2%) NA NA
SXT prophylaxis
Yes 321(91.5%) NA NA
*SXT: trimethoprim/sulphamethaxazole
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of some yeast species like I. orientalis, C. inconspicua and
C. norvegenesis which are intrinsically resistant to ﬂuconazole
being isolated from clinical specimens.15 In addition, the increased
use of antifungals especially azoles has resulted in multiple reports
of ﬂuconazole-resistant C. glabrata.14,15
In Tanzania, there are limited fungal diagnosis services
available and data on Candida spp. colonization and subsequently
causing infections in healthy individuals and immunocompro-
mised patients are still scarce. This comparative study was
designed to establish the prevalence and distributions of NAC
spp. colonizing HIV-infected and non-HIV infected individuals.
2. Materials and Methods
2.1. Study design and cohort
This comparative cross-sectional study was conducted in
Mwanza City, Tanzania between March and July 2015. Individuals
aged 1- 90 years without clinical signs of oral candidiasis were
recruited. Sample size was obtained using Kish Lisle formula
basing on the 30% prevalence of NAC spp. obtained from a study in
Nigeria among HIV-infected individuals.16 The minimum sample
size obtained was 323 HIV-infected individuals. In order to
compare the prevalence we also enrolled nearly double as many
non-HIV infected individuals as in the control group. HIV-infected
patients (n=351) were recruited from Care and Treatment Centre
(CTC) at Bugando Medical Centre (BMC). Non-HIV infected
individuals (n = 639) were recruited from primary school, second-
ary schools, university and patients relatives visiting BMC. HIV
status was conﬁrmed using the Tanzania National Rapid test
algorithms protocol.17
2.2. Data collection and processing
Social demographic data of the study participants were
collected using standardized data collection tool. For HIV-infected
patients, the most recent CD4+ count was obtained from ﬁles. Oral
rinse specimens were collected by having each participant hold
10 ml sterile normal saline in the mouth for 60 seconds, then spit
in the sterile container as previously described.18 Samples were
inoculated on Sabouraud’s Dextrose Agar supplemented with
50 mg/ml gentamicin and 50 mg/ml chloramphenicol (SDA)
(Oxoid, Basingstoke RG24 8PW, UK). Plates were aerobically
incubated at 35 8C for 24-48 h. Preliminary spp. identiﬁcation was
done on CHROMagar (OXOID, Hampshire, England) as previously
described.19 The conﬁrmation was done using matrix-assisted
laser desorption ionization-time of ﬂight (MALDI-TOF) mass
spectrometry (MALDI Biotyper, Bruker Daltonics, Bremen,
Germany) on extracted cells harvested from SDA.20,21
3. Data analysis
Data analysis was done using STATA version 11. Categorical
variables (sex, antibiotic use, use of HAART and trimethoprim/
sulphamethaxazole (SXT) prophylaxes use) were summarized in
the form of proportions and frequency tables, whereas median
(interquartile range) was used to summarize continuous variables
(age and CD4 count). Univariate and multivariate logistic regres-
sion analysis was done to determine factors associated with non-
albicans Candida colonization. Factors with 95% conﬁdence
interval (CI) and p-value of less than 0.05 were considered
statistically signiﬁcant. The medians CD4 count among HIV
infected individuals colonized and non-colonized with NAC spp.
were compared using Wilcoxon rank-sum (Mann- Whitney) test.3.1. Ethical consideration
Ethical clearance for conducting this study was granted by joint
CUHAS/BMC research ethics and review committee with certiﬁcate
number CREC/048/2014. All participants above 18 years of age
were requested to sign the written informed consent form and for
participants below 18 years their parents/guardians were
requested to assents for them before recruitment. All patient-
related information was stored in a pseudonymized form.
4. Results
The median age of HIV-infected patients was 38 (IQR 31-46)
years while that of non-HIV infected individuals was 30 (IQR 26-
36) years. The majority of HIV-infected patients (160/351, 45.6%)
had a history of antibiotics use two weeks prior enrolment. The
median CD4 count of the HIV-infected patients was 372.5 (IQR
195.5-559.5) cells/ml (Table 1).
Candida albicans was the commonest spp. detected in both
groups 119 (n = 351, 33.90%) of HIV-infected and 146 (n = 639,
22.9%) of non-HIV infected population (p = 0.023). NAC spp.
carriage was detected in 64 (n = 990, 6.46%) of the study
participants. Of HIV-infected patients, 36/351 (10.3%) carried
NAC spp., as compared to only 28/639 (4.4%) among non-HIV
infected (P = 0.0003). Only one HIV infected participant was
colonized by two NAC spp.
Of 351 HIV infected individuals; 10(2.8%), 9(2.6%) and 8(2.3%)
had Candida tropicalis, C. krusei (Issatschenki orientalis) and
C. glabrata respectively, while of 639 non-HIV infected individuals,
8(1.3%) and 5(0.9%) were colonized with C. dubliniensis and
C. tropicalis respectively (Table 2). Non-albicans Candida spp.
detected from HIV infected individuals were C. tropicalis 10(27.8%),
I. orientalis 9(25%), C.glabrata 8(22.2%) and others 9(25%)
Table 2. Out of 15 C. tropicalis, 12 I. orientalis and 12 C. glabrata
detected 10, 9 and 8 respectively, were from HIV infected
Table 3
Factors associated with non-albicans Candida colonization
Predictor NCA positivity OR(95%CI) P value Adjusted OR(95%CI) Adjusted P value
Sub analysis of HIV infected patients
Median Age* 36(27-43) 0.99(0.96-1.01) 0.352 0.992(0.97-1.02) 0.567
Sex
Male (89) 10(11.2%) 1
Female (262) 26(9.92%) 0.87(0.4-1.9) 0.725 1.001(0.43-2.8) 0.996
Median CD4* 251(120-380) 0.99(0.995-0.999) 0.007** 0.99(0.996-0.999) 0.01**
Antibiotic use
No (191) 15(7.85) 1
Yes (160) 21(13.13) 1.78(0.88-3.56) 0.108 2.2(1.03-4.74) 0.042**
SXT
No (30) 3(10.00) 1
Yes (321) 33(10.28) 1.03(0.29-3.58) 0.961 1.6(0.26-9.62) 0.62
HAART
No (8) 1(12.5) 1
Yes (343) 35(10.2) 0.79(0.95-6.65) 0.833 0.82(0.1-11.4) 0.88
Sub analysis of health control
Median Age* 1.02(0.99-10.3) 0.073 1.02(0.99-1.04) 0.07
Sex
Male (177) 7(3.95%) 1
Women (462) 21(4.55%) 1.16(0.48-2.77) 0.744 1.2(0.52-3.03) 0.621
Antibiotic use
No (606) 26(4.29%) 1
Yes (33) 2(6.06%) 1.44(0.33-6.34) 0.63 1.3(0.29-5.84) 0.72
Note: *median (Inter quartile range), ** statistically signiﬁcant variables and NCA positivity is Non albicans Candida positivity.
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HIV uninfected individuals 8/11 Table 2.
The median CD4 cell count among HIV-infected patients
colonized by non-albicans Candida spp. was 251 (IQR 170-380)
cells/ml, while for those not colonized by NAC spp. was 473 (IQR
304-673.5) cells/ml, P < 0.001.
On multivariate logistic regression analysis, among HIV-
infected individuals, as CD4 decreases by one unit the risk of
being colonized by NAC spp. increases by 1% (OR 1.01, 95% CI;
1.001-1.004, P = 0.001). Among HIV-infected individuals, those
with history of antibiotic use two weeks prior recruitment to the
study were more (OR = 2.2, p = 0.042) colonized by NAC spp. than
those with no history of antibiotic use (Table 3).
Non-albicans Candida colonization among HIV-infected
individuals without antibiotic use
Of 191 HIV-infected individuals without history of antibiotic
use, 15 (7.85%) were colonized by NAC spp., as compared to 26
(4.3%) of 606 HIV-uninfected individuals without history of
antibiotic use p = 0.026.
5. Discussion
Oral yeast (mainly Candida spp.) colonization remains one of
the major initial processes that can progress to infections if the
innate and adaptive immune system is disrupted.22 The increased
isolation of NAC spp. colonizing oral cavity is of public health
concern because of the possibility of Candida infections caused by
azole-resistant NAC spp., which are difﬁcult to treat.3,23 As it was
previously reported,2,3,22 HIV-infected individuals in the current
study had signiﬁcantly higher rates of colonization by NAC spp.
than non-HIV infected individuals, which can be explained by their
compromised immune status. The prevalence obtained in this
study is similar to that reported by Cartledge et al among HIV-
infected individuals.23
Multiple therapies and here mainly antibiotic treatment among
HIV-infected individuals is one of the factors that can inﬂuence oral
Candida colonization. In the current study, among HIV-infected
individuals history of antibiotic use was found to be a signiﬁcant
factor that can lead to oral colonization by NAC spp. Thisphenomenon has also been reported previously by Canon et al,24
whereby most of the participants with history of antibiotic use
were found be colonized by NAC spp. The ability of the broad-
spectrum antibiotics to alter the normal microbial ﬂora by killing
the bacteria and allowing the proliferation of Candida is thought to
explain the observed fact.15,25 However, HIV infection alone
without antibiotic use might also have inﬂuence on colonization
by NAC spp. as evidenced in this study. HIV-infected individuals
without history of antibiotic use had signiﬁcantly higher coloni-
zation rates by NAC spp. than HIV-uninfected individual without
history of antibiotic use.
Candida tropicalis, I. orientalis, C. glabrata and C. parapsilosis were
the most frequent NAC spp. isolated from HIV-infected individual
in the current study. This is of public health concern because some
of these Candida spp. are intrinsic resistant to ﬂuconazole which is
the commonly used azole in developing countries.26–29 I. oritentalis
is known to be natural resistant to ﬂuconazole while C. glabrata is
highly variable with an elevated ability to develop resistance.30
With an un-established fungal diagnosis to species level in
resource-constrained settings like Tanzania, the overuse of
ﬂuconazole in HIV and non HIV patients for prophylaxis and
empirical treatment might increase the problem of treatment
failure for NAC infections. This signiﬁes the importance of
improving fungal diagnostics especially in sub-Saharan Africa.
Findings of this study suggest that decrease of CD4 count as the
marker for immune status has inﬂuence on Candida carriage. This
was further conﬁrmed by the fact that the use of highly active
antiretroviral therapy (HAART) among HIV-infected individuals
was found to reduce the risk of oral NAC spp. colonization in the
current study. This same ﬁnding has also previously been reported
elsewhere.2,31
6. Conclusion
The prevalence of NAC spp. is high among HIV-infected
individuals with low CD4 count, placing them at higher risk of
invasive infections caused by these pathogens. Further studies
should be done to investigate the role of non-albicans Candida spp.
in causing invasive fungi infections among immunocompromised
patients.
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